Cynulliad Cenedlaethol Cymru

Yn ôl i Chwilio
WAQ78575 (e) Wedi’i gyflwyno ar 11/07/2019

Pa ystyriaeth y mae Llywodraeth Cymru wedi'i rhoi i sefydlu cynllun mynediad i gleifion ar gyfer Liothyronîn yng Nghymru?

Wedi'i ateb gan Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol Wedi'i ateb ar 16/07/2019

The Welsh Government has given no consideration to establishing a patient access scheme (PAS) for liothyronine.  

PAS arrangements are made under the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.  A PAS proposes a discount, rebate or other variation from the list price of a branded medicine when it is purchased by the NHS.  Liothyronine is a generic medicine, the price of which is determined by its manufacturer, with the cost of liothyronine to the NHS reflecting the price its manufacturers charge suppliers such as pharmacies. 

Archwilio Cynulliad Cenedlaethol Cymru